Multimodal Integration for PROs

• Multimodal integration for PROs is a framework that fuses patient-reported outcomes with clinical, sensor, omics, and environmental data to enable personalized decision support.
• Advanced frameworks employ tailored preprocessing, neural architectures, and fusion mechanisms to harmonize heterogeneous data for robust patient-centered assessments.
• Key challenges such as data missingness, bias, and scale incompatibility drive ongoing research in precision phenotyping and adaptive healthcare delivery.

Multimodal integration for patient-reported outcomes (PROs) refers to the systematic fusion of heterogeneous data sources—including self-reported health measures, clinical records, sensors, omics, and environmental variables—to achieve robust inference for patient-centered outcomes, precision phenotyping, and adaptive healthcare delivery. PROs, which encompass standardized instruments (PROMs), event reports (PREMs), and individualized quality-of-life measures, present unique challenges: subjectivity, temporal sparsity, high missingness, and scale incompatibility with biomedical, digital, and contextual health data. Advanced multimodal data science frameworks explicitly tackle these challenges by employing architectural, statistical, and workflow innovations that enable PROs to guide clinical decision support, risk modeling, and trial optimization alongside objective measures.

1. Data Modalities for Multimodal PRO Integration

Recent frameworks integrate a diverse set of modalities with PROs to form comprehensive digital health representations. These include:

• Structured clinical data: EHR-derived variables such as demographics, diagnoses, medications, vitals, and labs.
• Sensor/wearable streams: Longitudinal data (e.g., heart rate variability, accelerometry, sleep architecture) from consumer or medical devices.
• Social and environmental context: SDOH, psychosocial stressors, socio-exposome features, and sociodemographic factors.
• Multi-omic assays: Genomics, transcriptomics, proteomics, metabolomics, and microbiome profiles.
• Allostatic biomarkers: Measures of physiological stress and chronic disease (e.g., cortisol, CRP, HbA1c).
• Unstructured text: Clinical notes, provider narratives, and free-text PROs.
• Medical images: Radiology and pathology data.

Preprocessing protocols are tailored per modality: scaling/tabular harmonization for numeric measures, advanced imputation (mean, mode, MICE, k-NN) for high-missingness fields, log/batch correction for omics, transformer-based embeddings for text, and deep learning pipelines (resizing, augmentation) for images. PROs are numerically normalized (e.g., 0–100 for PROMs) or LLM-embedded for narrative inputs. Sensor streams are temporally aggregated, interpolated, and z-scored as required (Amoei et al., 2024, Cosentino et al., 2024, Sun et al., 2024, Minoccheri et al., 24 Jun 2025).

2. Model Architectures and Fusion Mechanisms

Multimodal integration for PROs employs a range of neural and statistical architectures, with explicit fusion mechanisms:

• Multi-agent frameworks: Each human outcome domain (short- and long-term clinical, resource, mental health, patient-centered PROs) is modeled by a dedicated agent selecting best-fit paradigms (gradient-boosted trees or feed-forward nets for structured data, LSTM/transformers for time series, LLMs for text, convolutional or vision transformers for images). Agent outputs (“recommendation embeddings”) are fused by a meta-agent, typically via concatenation and attention-based weighting, enabling late fusion and conflict resolution with human-in-the-loop oversight (Amoei et al., 2024).
• Adapter-based LLM schemes: Time-series features (e.g., per-channel means/variances of wearable data) are mapped by an MLP adapter into learned “prefix” tokens, concatenated with text-based PRO prompts as LLM input. This enables seamless transformer-based multimodal contextualization (Cosentino et al., 2024).
• Tensor and matrix factorizations: SCMTF for PRO phenotyping in chronic disease decomposes a tensor (patients × temporal features × time-windows, capturing both PROs and labs) and a matrix of static features, coupled via shared patient factors, nonnegativity constraints, per-feature/patient biases, and end-to-end supervision by relevant downstream outcome classifiers (Minoccheri et al., 24 Jun 2025).
• End-to-end real-time pipelines: Sensor and PRO streams ingested via mobile apps are temporally windowed, normalized, and mapped to standardized JSON objects, enabling alert-fused visualization and decision support in EHR-integrated dashboards (Sun et al., 2024).

Fusion can occur at various levels: input (concatenation, joint embedding), intermediate (cross-modal attention or transformer blocks aligning modalities), or output (late meta-agent fusion). Most current practice is late-stage fusion, but research points toward joint cross-modal transformer architectures as an emerging direction (Amoei et al., 2024).

3. Mathematical Formalisms and Optimization Strategies

Multimodal PRO integration commonly adopts multi-task and regularized optimization routines. A generic loss function for multi-agent architectures is:

$$L(\Theta) = \sum_{i\in\text{Outcomes}} \lambda_i \cdot \ell_i(y_i, \hat{y}_i; \Theta_i) + \alpha\cdot R(\Theta)$$

where $y_i$ are observed outcomes (incl. PROs), $\hat{y}_i$ are predictions, $\ell_i$ are domain-appropriate losses (MSE for continuous PROs, cross-entropy for categorical targets), $\lambda_i$ are clinically driven weights, and $R(\Theta)$ penalizes complexity (e.g., L2, trace-norm) (Amoei et al., 2024). In Bayesian settings, $-\log p(\Theta)$ terms model parameter uncertainty.

Matrix-tensor factorization approaches minimize a sum of reconstruction loss (imputation accuracy for noisy/missing PROs and labs), cross-entropy for outcome supervision, per-feature/patient bias adjustment, and L1 sparsity, under nonnegativity constraints and simultaneous end-to-end gradient-based optimization (e.g., Adam plus projection steps) (Minoccheri et al., 24 Jun 2025). LLM adapter systems separately train lightweight fusion modules atop frozen transformer weights (Cosentino et al., 2024).

Dose-finding designs employ weighted likelihoods and marginal posterior updates, allowing partial follow-up of each modality (e.g., time-to-toxicity for PROs and clinician toxicity), with fused dose recommendations made via joint constraints (Andrillon et al., 2023).

4. Evaluation Metrics and Validation Approaches

Multimodal PRO models are assessed using standard and domain-specific metrics:

• Regression (continuous PROs): Root mean square error (RMSE), mean absolute error (MAE), concordance correlation.
• Classification (categorical/binary PROs): AUROC, AUPRC, F1-score.
• Comparative evaluations: Incremental $\Delta R^2$ or $\Delta$AUC between single-modality and multimodal systems, bootstrapped confidence intervals, and statistical tests (e.g., DeLong’s for AUC) (Amoei et al., 2024, Cosentino et al., 2024, Minoccheri et al., 24 Jun 2025).
• Phenotype interpretability: Random Forest feature importance, temporal dynamic visualization of latent phenotypes, and domain expert review (Minoccheri et al., 24 Jun 2025).
• Clinical workflow: Adherence rates, yield, notification efficacy, and usability metrics in pilot deployments (Sun et al., 2024).

Hold-out splits are typically stratified across key demographics and PRO stratifications; k-fold cross-validation ensures robust estimation. Continuous local validation and fine-tuning address PRO pattern drift (Amoei et al., 2024).

5. Challenges: Bias, Generalizability, and Missingness

PRO data are susceptible to missingness, subjectivity, and subgroup coverage imbalances. Audit protocols continuously monitor residuals across age, gender identity, ethnicity, and SES strata. Remediation strategies include:

• Task/sample reweighting to ensure proportional contribution from underrepresented PRO profiles.
• Adversarial debiasing heads penalizing protected-attribute leakage in latent embeddings.
• Local retraining of foundation models to suppress external, proprietary bias sources (Amoei et al., 2024).
• Imputation within factorization frameworks via masked entries and low-rank reconstructions (SCMTF tolerates >90% missing PROs) (Minoccheri et al., 24 Jun 2025).
• Bayesian and frequentist modeling of delayed/partial follow-up in dose-finding scenarios, enabling robust dose recommendations even with high PRO missingness (Andrillon et al., 2023).

Generalizability is promoted by continuous validation and fine-tuning, recurrent learning loops (“learning healthcare system” paradigm), and multilevel cross-modal supervision.

6. Interpretability and Clinical Integration

Explainability is central for decision support in multimodal PRO systems. Methods include SHAP decomposition across concatenated vectors (illustrating the relative contribution of PROs, SDOH, and omics), attention heatmaps in cross-modal transformers, and counterfactual “prototype” generation (“If symptom X were 1 point lower, predicted QOL increases by $\Delta$”) (Amoei et al., 2024).

Clinical integration depends on seamless presentation in EHR dashboards, live alerting on adverse PRO predictions, export to structured formats (CSV/JSON/FHIR), and closed-loop feedback (reinforcement learning on clinician workflow adjustments). User-facing metrics (e.g., response rates, real-time alert latency, and workflow usability) have demonstrated high adherence and practicality in pilot studies (Sun et al., 2024).

7. Limitations and Future Directions

Current frameworks remain limited by:

• Lack of detailed, empirically validated preprocessing and fusion strategies for PROs at scale (Amoei et al., 2024).
• Absence of systematic benchmarks and error analysis for PRO-centric prediction.
• Conceptual, rather than fully instantiated, cross-modal fusion architectures (e.g., intermediate transformers for joint embedding).
• Technical challenges in harmonizing individualized PROMs, high-frequency sensor proxies, and self-supervised pretraining on raw analog signals (Cosentino et al., 2024, Amoei et al., 2024).

Prospective extensions include real-time integration of wearable-derived PRO proxies, active learning for digital PRO surveys, retrieval-augmented fill-in of historical PRO gaps, end-to-end cross-modal transformers trained directly on heterogeneous patient records, and graph-based fusion models linking PRO, omic, and environmental variables (Amoei et al., 2024, Cosentino et al., 2024, Minoccheri et al., 24 Jun 2025). In trial design, generalization to imaging-derived endpoints, sensor-driven toxicity events, and ordinal outcome models has been conceptually outlined (Andrillon et al., 2023).

A plausible implication is that as multimodal integration matures, PROs will increasingly exert primary influence on adaptive clinical algorithms, supporting individualized, patient-centered care at scale.